Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

By sjmartinez • May 30, 2025

Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes. Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710-w. Epub ahead of print. PMID: 40439821.

Tags: breast cancer, circulating tumor DNA, Genomics, Hematology/Oncology, Liquid biopsy., Publications

Related Posts

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits[...]

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I,[...]

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq[...]